Retrospective Study
Copyright ©The Author(s) 2022.
World J Cardiol. May 26, 2022; 14(5): 307-318
Published online May 26, 2022. doi: 10.4330/wjc.v14.i5.307
Table 1 Descriptive statistics of variables in data set by adverse event for 471 patients with percutaneous coronary intervention
No MACE (n = 324)
Had MACE (n = 147)
n
mean
SD
n
mean
SD
Systolic SD32413.726.0214715.385.26
Diastolic SD3248.543.111478.932.71
Systolic LC32437.1114.7914744.3115.42
Diastolic LC32423.607.7814726.379.09
Systolic average324131.8311.47147132.2011.63
Diastolic average32474.827.7514771.337.64
Number of BP readings32440.1935.8614762.8152.85
Mean days between readings32459.0737.0414742.1930.70
Age32267.8711.2114770.6911.86
Pre PCI LVEF25256.4411.7312253.0613.63
Pre creatinine3071.150.981381.501.19
n%n%
Sex469
Male11074.8322870.37
Female3725.179429.01
Race469
White14296.6031296.30
Other53.40103.09
Hispanic10.6841.23
Smokes4672214.975115.74
Has hypertension46913591.8426682.10
Has diabetes4696745.5812237.65
Had prior CVD4693926.536820.99
Had prior MI47010632.726342.86
Had prior PCI47012538.586745.58
Had prior CABG4705316.364127.89
Prior creatinine445
0 to 229691.3611880.27
> 2 to 582.471812.24
> 530.9321.36
Anginal class469
No symptoms3322.45247.41
CCS I117.483912.04
CCS II2718.378726.85
CCS III4329.259529.32
CCS IV3322.457723.77
On anti-anginal medication46911477.5520462.96
Beta-blockers9866.6716450.62
Calcium channel blockers3725.177623.46
Long-acting nitrates3322.454112.65
Ranolazine32.0420.62
Indication471
Non-STEMI8255.7816751.54
STEMI96.123912.04
Other stage5638.1011836.42
MACE within 1 yr471
Readmission13127.81
MI479.98
Death214.46
CVA61.27